drugset / Trial / NCT01659138

Efficacy and Safety of SAR339658 in Patients With Moderate to Severe Ulcerative Colitis

NCT01659138 ↗

Phase 2 Terminated 28 enrolled Sanofi
RandomizedParallel-groupDouble-blindTreatment

Summary

Primary Objective: To assess the efficacy of SAR339658 Secondary Objective: To assess the safety of SAR339658

Timeline

Start
2012-08
Primary completion
2014-06
Completion
2016-04

Outcome

Outcome not reported

Stopped (Enrollment): “Recruitment was early terminated due to slow recruitment. Not linked to any safety concern.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Vatelizumab Monoclonal antibody — Intravenous

Indications